SEC Form 4 · accession 0001127602-18-032273
BIOCRYST PHARMACEUTICALS INC · BCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas R Staab II
Officer — Senior Vice President and CFO
Period of report
Nov 2, 2018
Accepted (ET)
Nov 6, 2018 · 4:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882796
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 2, 2018 | M | 7,356 | $3.22 | A | 144,739 | D | |
| Common StockF1,F2 | Nov 2, 2018 | S | 7,356 | $7.78 | D | 137,383 | D | |
| Common StockF1 | Nov 2, 2018 | M | 3,500 | $3.78 | A | 140,883 | D | |
| Common StockF1,F3 | Nov 2, 2018 | S | 3,500 | $7.96 | D | 137,383 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Emp. Stock Option (Right to Buy)F1 | $3.22 | Nov 2, 2018 | M | 7,356 | D | May 23, 2017 | May 23, 2026 | Common Stock | 7,356 | 115,571 | D |
| Emp. Stock Option (Right to Buy)F1 | $3.78 | Nov 2, 2018 | M | 3,500 | D | Jul 1, 2012 | Jul 1, 2021 | Common Stock | 3,500 | 45,805 | D |
Explanation of responses
- F1The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018.
- F2The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.74 to $8.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
- F3The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.95 to $7.96. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.